BELLUS Health (TSE:BLU) was downgraded by Guggenheim from a “buy” rating to a “neutral” rating in a report issued on Tuesday, BayStreet.CA reports.
Separately, HC Wainwright restated a “buy” rating on shares of BELLUS Health in a research note on Friday, June 26th.
TSE BLU traded down C$11.85 during trading on Tuesday, hitting C$4.53. 3,231,236 shares of the company traded hands, compared to its average volume of 144,944. BELLUS Health has a 12 month low of C$3.40 and a 12 month high of C$16.68. The business has a fifty day simple moving average of C$14.39 and a 200 day simple moving average of C$12.61. The company has a market capitalization of $855.52 million and a P/E ratio of -7.40. The company has a current ratio of 15.47, a quick ratio of 15.01 and a debt-to-equity ratio of 0.12.
BELLUS Health (TSE:BLU) last issued its quarterly earnings data on Thursday, May 14th. The company reported C($0.24) earnings per share for the quarter, beating the Zacks’ consensus estimate of C($0.25) by C$0.01. The company had revenue of C$0.01 million during the quarter, compared to the consensus estimate of C$0.01 million.
In related news, insider Orbimed Advisors LLC sold 36,400 shares of BELLUS Health stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of C$14.08, for a total transaction of C$512,657.60. Following the completion of the transaction, the insider now directly owns 1,182,416 shares of the company’s stock, valued at approximately C$16,653,146.94. Also, Director Francesco Bellini purchased 50,000 shares of BELLUS Health stock in a transaction on Monday, July 6th. The stock was purchased at an average price of C$3.82 per share, for a total transaction of C$191,058.00. Following the completion of the transaction, the director now owns 397,479 shares of the company’s stock, valued at C$1,518,830.86.
About BELLUS Health
BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease.
Further Reading: What is a good rate of return for a mutual fund?
Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.